REGENSBURG, GERMANY--(Marketwire - April 16, 2010) - Geneart AG / The Management Board and
the Supervisory Board of the GENEART AG Recommends the Acceptance of the
Applied Biosystems/Life Technologies Voluntary Public Offer processed and
transmitted by Hugin AS. The issuer is solely responsible for the content
of this announcement.
Regensburg, April 16, 2010 - The Management Board and the Supervisory
GENEART AG have announced their joint statement with respect to the
public offer by Applied Biosystems Deutschland GmbH to the
GENEART AG. This joint statement is in reference to the offer document
by the Applied Biosystems Deutschland GmbH (affiliate of the Life
Group) on April 13, 2010.
The Management Board's and the Supervisory Board's joint statement
downloaded from GENEART AG's website at
www.geneart.com. It is explicitly advised that the German Takeover Act
(WpÜG) does not apply to the offer for acquisition of GENEART AG shares.
not a statement pursuant to the WpÜG.
For further inquiries, please contact:
Dr. Karoline Stürmer
Phone: (0)941-942 76-417
Fax: (0)941-942 76-711
Better Orange IR & HV AG
This document may contain estimates, prognoses and opinions about company
and objectives, products or services, future results, opinions about
results or opinions leading up to these results. All these projections
future are subject to risk, uncertainty and unforeseeable change
control of the GENEART Group. Many factors may lead to actual results,
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000 GENEART entered the Gene Synthesis market and has since
global market leader. Today, the company is one of the leading
the Synthetic Biology field. Experts at GENEART provide key technologies
development and production of new therapeutics and vaccines. Customers also
advantage of GENEART services to customize enzyme attributes, such
attributes of enzymes used as detergent additives, and to construct
which produce complex biopolymers or break down polymers, such as
petroleum components, etc. GENEART's service portfolio ranges from
optimization and production of synthetic genes according to DIN EN
9001:2008, to the generation of gene variants or complex gene libraries
production of cell lines, to the development and production of DNA and
based drug candidates. GENEART AG in Regensburg and its subsidiaries
Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ
180 people. The company is listed on the German Stock Exchange since May
Since April 2010, the US-American Life Technologies Corporation, one
leading biotechnology companies worldwide with 2009 revenues of 3.3B
dollars and about 9,000 employees, is majority shareholder of GENEART AG.
Josef-Engert-Str.11 Regensburg Germany
Press release (PDF): http://hugin.info/136633/R/1404472/358578.pdf